Hunting PLC reported first-half 2026 results showing lower revenue and EBITDA, but highlighted strong growth in Subsea Technologies and Perforating Systems, record international sales, and progress on organic oil recovery...
Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners...
Hunting PLC reported first-half 2026 results showing lower revenue and EBITDA, but highlighted strong growth in Subsea Technologies and Perforating Systems, record international sales, and progress on organic oil recovery. The group declared a higher interim dividend, advanced cost cuts and restructuring, and cut full-year EBITDA guidance after delays to Kuwait tendering...
Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners...
